Story

The Full Story

From 2021 to 2024, Hims told an unusually consistent story: a multi-specialty telehealth subscription business scaling toward profitability. Q2 2024 broke the pattern when the compounded GLP-1 launch reshaped the growth algorithm, the risk profile, and ultimately the company's identity. Management has delivered every quarterly guide through 2025 and beat two sets of "long-term" targets on an accelerated timeline — but the Novo Nordisk partnership collapse, FDA naming, DOJ referral, and Q4 2025 subscriber deceleration mark the first genuine credibility stress in the company's public-market history. The current $6.5B 2030 revenue target is now the central stake.

Credibility Score (1–10)

6.5

1. The Narrative Arc

The story has rewritten itself roughly every four quarters — each time expanding the TAM rather than admitting to an earlier overpromise. The result is an arc that looks confident on the surface but reveals quietly retired promises at each inflection.

No Results

**Five defining pivots:** (1) Q2 2023 "personalization" reframe; (2) Q4 2023 profitability pull-forward; (3) Q2 2024 GLP-1 launch; (4) Q1 2025 $6.5B global platform target; (5) Q4 2025 "curator / consolidator" retelling. Each pivot expanded the story rather than walking it back — until the Novo Nordisk breakup forced the first forced retelling.

2. What Management Emphasized — and Then Stopped Emphasizing

Topic emphasis has rotated sharply. Themes that dominated 2023 letters ("four strategic pillars," "access") quietly disappeared by 2024. "GLP-1 / compounded weight loss" went from dominant in 2024 to retroactively demoted by Q4 2025 ("majority of 2025 revenue came from non-GLP-1 offerings"). Intensity scored 0 (absent) to 5 (headline theme).

Three patterns stand out:

"Four strategic pillars" (trusted brand / technology / product innovation / clinical excellence) — the central 2023 framing — was wiped from the letters by Q1 2024 without acknowledgment.
GLP-1 went from one-phrase mention (Q2 2023) to headline theme (Q2 2024 through Q1 2025) to retroactive demotion (Q4 2025) when the Novo Nordisk partnership collapsed.
International + Labs + Longevity/Peptides are the new dominant themes — all three were absent before Q4 2024. The story is being recomposed faster than the underlying business can prove it.

3. Risk Evolution

The 10-K risk factors track the business transformation with a roughly 4-quarter lag. Pandemic and "early-stage business" risk language retired as the company matured. All of the most severe current risks (GLP-1, compounding, FDA/FTC scrutiny, international regulation, $1B convertible leverage, Eucalyptus integration) are new since FY2024.

Dropped quietly: "limited operating history" (bullet removed from FY2024 summary); pandemic tailwind reversal (removed FY2024); Truepill partner-pharmacy reliance (Truepill dropped from filings from FY2023 onward as internal fulfillment scaled).
New and severe in FY2024: GLP-1 compounded drug risk; 503B outsourcing facility regulation; perception of safety/efficacy of compounded drugs; AI-related regulatory and reputational exposure.
New and severe in FY2025: FDA warning letters (Sep 2025, explicitly naming Hims); HHS referral to DOJ (Feb 2026); Novo Nordisk patent infringement lawsuit; Eucalyptus acquisition integration risk; $1.0B 2030 convertible notes debt service; LDT/clinical lab regulation (post-Trybe); multi-jurisdictional foreign regulation (Canada PHIPA, UK MHRA/GPhC, EU EMA); tariff/trade actions. The risk profile in FY2025 is unrecognizable from FY2021.

4. How They Handled Bad News

The pattern is consistent: quick reframes, light on direct admission. Major negative events — the FDA shortage resolution, the Novo Nordisk termination, the sexual-health slowdown, Q4 2025 subscriber deceleration — were each reframed as strategic evolution rather than confronted as setbacks.

No Results

The **Super Bowl + Novo Nordisk + FDA/DOJ story** is the single largest credibility gap in the letters. Every major regulatory and partnership event from 2024–2026 was either omitted from or minimized in the CEO shareholder letters, with disclosure occurring only in the 10-K risk factors. This is a systematic pattern of **reframe-over-confront**.

5. Guidance Track Record

Hims met or beat every quarterly guide from FY2023 through FY2025. But the bigger story is in the long-dated promises: each one was either pulled forward aggressively (a positive signal) or quietly retired (a negative one).

No Results

Credibility observations:

FY2023 and FY2024 were massive beats — the original 2025 "$1.2B rev / $100M EBITDA" target was delivered a full year early and blown past by 48% on EBITDA.
FY2025 was an "on-target" year — first time a major guide landed at midpoint rather than beating, signaling the growth algorithm stabilizing.
FY2026 is the first guide with Adj. EBITDA midpoint below the prior year's actual ($337M vs $318M FY25). Implied revenue CAGR to hit the 2030 $6.5B target from FY25 is ~29% — achievable, but the first-year step is 18% at midpoint.
The $725M 2025 weight-loss promise is the cleanest example of a quiet retirement — never reported against, retroactively diluted by "the majority of 2025 revenue came from non-GLP-1 offerings."

6. What the Story Is Now

The current story is "largest consumer-first personalized health platform, globalizing via acquisition, with GLP-1 as a contributing vertical." That is a meaningfully different pitch than "the telehealth subscription compounder with $725M of weight loss revenue" that prevailed through Q1 2025.

What has been de-risked:

Profitability is real — three straight years of GAAP operating profit, $2.35B revenue, 14% Adj. EBITDA margin, though inflated by a one-time $54M tax benefit in FY2024.
Personalized offerings are now >70% of US revenue and drive higher monthly revenue per subscriber ($81 in FY25 vs $51 in FY21).
Compounded GLP-1 regulatory overhang is partially resolved via the March 2026 Novo Nordisk agreement (distributing branded Wegovy/Ozempic; Novo dropped its lawsuit).

What still looks stretched:

The 2030 $6.5B / $1.3B target requires revenue CAGR of ~29% from FY25 — while FY26 initial guide implies only 15–23% and subscriber growth decelerated to +13% YoY in Q4 25.
Margin math — branded Wegovy distribution carries structurally lower margin than compounded; FY26 Adj. EBITDA midpoint is already below FY25 actual; the "20% long-term margin" promise is not yet earned.
International is the single largest remaining TAM expansion claim (>$1B in 3 years). ZAVA, Medici, Eucalyptus, YourBio — four acquisitions in 12 months — are not yet integrated and have consumed most of the FCF (collapsed from $198M to $57M in a single year). Eucalyptus integration is flagged as a brand-new risk section in the FY2025 10-K.
Peptides / longevity is a narrative-heavy, evidence-light vertical dependent on regulatory loosening (RFK Jr. push). It is priced into the story but not yet into the P&L.

What to believe vs. discount:

**Believe:** The execution muscle is real. Four consecutive years of beating or meeting guidance; strong customer unit economics; genuine share gains in personalized care; profitability at scale.

**Discount:** The long-dated targets until management shows one full year of post-GLP-1 shortage organic growth. Also discount the communication style — the letters systematically understate setbacks, reframe misses, and omit the most relevant regulatory events. The 10-K is where the truth lives; the shareholder letters are where the story lives.